Skip to main content
Equibles

Alethia Young

Analyst

Cantor Fitzgerald

Analyst

Cantor

LENZ Therapeutics, Inc. (LENZ)

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Alethia Young

Alethia Young is recorded as Analyst at Cantor Fitzgerald and Analyst at Cantor. LENZ Therapeutics, Inc. reported in an 8-K filed June 23, 2023 that Alethia Young resigned as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective June 30, 2023. The proxy statement of LENZ Therapeutics, Inc. reports total compensation of $1,835,489 for Alethia Young in fiscal 2022, including a base salary of $337,500. Alethia Young has spoken on 1 earnings call across 1 company, most recently for Vertex Pharmaceuticals Inc / Ma on October 29, 2020.

“On June 19, 2023, Alethia Young, the Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of Graphite Bio, Inc. (the "Company"), notified the Company of her decision to resign, effective at the close of business on June 30, 2023.”
LENZ Therapeutics, Inc. Form 8-K, filed June 23, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at LENZ Therapeutics, Inc.

Other people whose current roles at this company are on record from its filings.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2022 LENZ Therapeutics, Inc. (LENZ) $337,500 $1,835,489

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.